@Jolly said in CMS releases negotiated price list:
Yeah, but...
How many new drugs does the developing world need? Let's take something like erythromycin...For years erythromycin was dirt cheap, especially when compared with zithromax. Erythromycin had the disadvantage of more frequent and more total doses, but both antibiotics were killing essentially the same bugs.
There are multiple drugs like that out there and I suspect physicians in those countries often choose the cheapest drug that is effective.
Mostly for diseases we can’t now cure. Gene therapies for sickle cell anemia are in trials now. Africa is the largest market by patient count. US by dollar volume.
I think it's going to be very interesting when the patents run out on the first-generation biologicals.
Depends on which. Plasma products, for example, are very different as there are actual diseconomies of scale. (To get a marginal new plasma donor generally costs more than your existing donors). So the economics are very different.
(By the way, gene therapies are considered biologics by the FDA so they’ll stay relevant for the foreseeable future)